Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Plavix Sales Help Bristol-Myers Swing To Q4 Profit

By Pharmaceutical Processing | January 27, 2009

NEW YORK (AP) — Strong sales of blockbuster blood thinner Plavix helped Bristol-Myers Squibb Co. post a sizable fourth-quarter profit Tuesday, rebounding from a loss in a charge-laden quarter a year earlier and beating Wall Street’s profit forecast.The New York-based maker of Abilify for bipolar disorder and Avapro for high blood pressure reported net income of $1.24 billion, or 63 cents per share, in the October-December quarter. A year ago, Bristol-Myers reported a net loss of $89 million, or 5 cents per share, due to large charges for restructuring and losses from investments in subprime securities. Excluding a host of one-time items, fourth-quarter profit would have totaled 46 cents per share. Those items included $260 million in payments to partner biotechnology company Exelixis Inc., $151 million for restructuring and an $870 million gain after expenses for selling Bristol’s ImClone Systems Inc. stock after losing its bid to buy ImClone to rival Eli Lilly & Co. Revenue totaled $5.25 billion, up 4 percent from $5.06 billion in 2007’s fourth quarter. Unfavorable currency exchange rates pulled down revenue by 4 percent, the company said. Analysts polled by Thomson Financial expected, on average, earnings per share of 41 cents and revenue of $5.43 billion. Pharmaceutical sales totaled $4.5 billion, led by Plavix at $1.47 billion, Abilify at $606 million, Avapro at $316 million and HIV drugs Reyataz and Sustiva at $329 million and $300 million, respectively. Sales from the Mead Johnson Nutrition division, the maker of Enfamil formula, were up 6 percent at $707 million. “We’ve executed with speed and rigor against our strategy. Results this quarter continued to be strong, capping off an outstanding year,” Chief Executive Jim Cornelius said in a statement. “Our favorable cash position expedites our business development efforts,” he added.Bristol-Myers said it has a total of $8 billion in cash and cash equivalents on hand, and its net cash position improved by $300 million to $1.5 billion in the quarter. The company forecast a lower 2009 profit of $1.85 to $2 per share, excluding one-time items, or $1.58 to $1.73 including items. Analysts on average expect earnings of $1.95 per share excluding items. For the full year, net income totaled $5.25 billion, or $2.63 per share. That was nearly 2 1/2 times the $2.17 billion, or $1.09 per share, profit for 2007. Revenue rose 13 percent, to $20.6 billion from $18.2 billion in 2007.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE